CD8+ T‐cell‐mediated JAK–STAT, NF‐κB, and MAPK signaling pathways are enriched in IPF patients [168], with inhibitors of these pathways showing therapeutic promise. Here, CD8A is linked to idiopathic pulmonary fibrosis.